CCEL Stock Overview
Engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
Cryo-Cell International, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.83 |
| 52 Week High | US$9.50 |
| 52 Week Low | US$4.48 |
| Beta | 0.57 |
| 1 Month Change | -6.23% |
| 3 Month Change | 26.09% |
| 1 Year Change | 33.16% |
| 3 Year Change | -36.75% |
| 5 Year Change | 8.45% |
| Change since IPO | -5.09% |
Recent News & Updates
Shareholder Returns
| CCEL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -0.06% | -4.1% | -2.4% |
| 1Y | 33.2% | -10.2% | 23.4% |
Return vs Industry: CCEL exceeded the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: CCEL exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| CCEL volatility | |
|---|---|
| CCEL Average Weekly Movement | 10.4% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CCEL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CCEL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 85 | David Portnoy | www.cryo-cell.com |
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer’s disease, Parkinson’s diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells.
Cryo-Cell International, Inc. Fundamentals Summary
| CCEL fundamental statistics | |
|---|---|
| Market cap | US$63.11m |
| Earnings (TTM) | -US$8.93m |
| Revenue (TTM) | US$31.84m |
2.0x
P/S Ratio-7.1x
P/E RatioIs CCEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CCEL income statement (TTM) | |
|---|---|
| Revenue | US$31.84m |
| Cost of Revenue | US$12.12m |
| Gross Profit | US$19.71m |
| Other Expenses | US$28.64m |
| Earnings | -US$8.93m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 61.92% |
| Net Profit Margin | -28.04% |
| Debt/Equity Ratio | -112.2% |
How did CCEL perform over the long term?
See historical performance and comparisonDividends
3.2%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 05:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2023/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cryo-Cell International, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Allen Klee | Maxim Group |